BNET Industries

Barrier Therapeutics Inc.

(BTRX) is in the Pharma Industry

Market Cap:$239.0K
Last Fiscal Year Sales:$24.0M
  • Public
  • US
Dow Jones Description

BARRIER THERAPEUTICS is a pharmaceutical company focused on the development and commercialization of pharmaceutical products in the field of dermatology. Our goal is to develop a portfolio of innovative products that address major medical needs in the treatment of dermatological diseases and disorders. Our product pipeline includes marketed products as well as product candidates in various stages of clinical development.

Chief Executive OfficerGeert Cauwenbergh PhD
Number of Employees 130
Contact Information

600 College Rd E Ste 3200

Princeton, New Jersey 08540

www.stiefel.com

(609) 945-1200

NAICS Code Pharmaceutical Preparation Manufacturing: 325412

News & Analysis

Filter by

barrier therapeutics inc. - All News and Analysis

  • International Stem Cell Receives Second $1M Tranche Under $5 Million Financing

    - 2009-01-23

    OCEANSIDE, Calif. -- International Stem Cell Corporation (OTCBB:ISCO) has received the second $1 million tranche of an anticipated private equity financing of up to $5 million to be funded over the next several months. The total amount of the financing is intended to allow the Company to move forward with...

  • Stiefel completes acquisition

    - 2008-09-01

    Stiefel Laboratories has completed its purchase of Barrier Therapeutics, a Princeton, N.J.-based company that has three topical products on the market, Xolegel, Vusion, and Solage. "Barrier's innovative products and pipeline are a very valuable addition to Stiefel," company CEO Charles W. Stiefel said in a statement. With the purchase of...

  • Stiefel purchase

    - 2008-08-18

    Stiefel Laboratories Inc. has completed its tender offer for the outstanding shares of Barrier Therapeutics Inc. Stiefel describes itself as the world's largest independent pharmaceutical firm focusing on dermatology...

  • Barrier Therapeutics Introduces Dual-Component Xolegel CorePak(TM) for Seborrheic Dermatitis

    - 2008-07-28

    Barrier Therapeutics, Inc. (NASDAQ: BTRX)announced today the introduction of Xolegel CorePakTM for the treatmentof seborrheic dermatitis. Now, patients with this chronic skin conditionneed only one prescription to get quick itch relief and to safely managethe overall condition long term. The two products in Xolegel CorePak are new XebcortTM Gel,...

  • Stiefel to buy Barrier Therapeutics

    - 2008-07-14

    CORAL GABLES, Fla. -- Stiefel Laboratories Inc. has agreed to acquire Barrier Therapeutics Inc. for $148 million. The deal, expected to close by the end of the third quarter, underscores Stiefel's drive to search for and develop premium, innovative dermatology products and focus on providing a superior customer...

  • Skin deep

    - 2008-07-01

    Like all the other assets of his specialty pharmaceuticals company, Alfred Altomari, the newly appointed CEO of Princeton, N.J.-based Barrier Therapeutics, hails from Johnson & Johnson. But while most of those assets--namely patent licenses for dermatology products not deemed worthy of development--were happily offloaded by the powerhouse drug company in...

  • Stiefel Labs in $148M Dermatology Deal

    - 2008-06-30

    Stiefel Laboratories Inc., a privately held Coral Gables, Fla.-based pharmaceutical company focused on dermatology, last week announced that it will acquire Barrier Therapeutics of Princeton for $148 million. Stiefel said it would pay $4.15 for every share of Barrier, or a 73 percent premium to its 30-day average closing...

  • Barrier doubles after $148 million Stiefel buyout

    - 2008-06-30

    Barrier Doubles after $148 Million Stiefel Buyout. Barrier Therapeutics Inc. Princeton NJ, the maker of skin-care drugs, more than doubled last week in Nasdaq trading after Stiefel Laboratories Inc. Coral Gables FL said it would buy the company for $148 million. Barrier, which sells three skin products, closed the week...

  • Wall Street News Alert: Breaking News Alert - NTRO! June 24, 2008

    - 2008-06-24

    Wall Street News Alert's "stocks to watch" thismorning are: Nitro Petroleum, Inc. (OTCBB: NTRO), ConocoPhillips (NYSE: COP), Barrier Therapeutics, Inc. (NASDAQ: BTRX) and Corn ProductsInternational, Inc. (NYSE: CPO). Nitro Petroleum, Inc. (OTCBB: NTRO) continues to make progress, and thecompany should be a "must see" for investors looking to possibly benefitfrom...

  • Story Stock for Tuesday, June 24, 2008: NPHS Summer Sales Growth!

    - 2008-06-24

    TheSUBWAY.com announces the following stocks toits Action List: NextPhase Wireless (OTCBB: NPHS), Barrier Therapeutics,Inc. (NASDAQ: BTRX), Royale Energy, Inc. (NASDAQ: ROYL), Level 3Communications, Inc. (NASDAQ: LVLT). Visit TheSUBWAY's Small Cap Investor Forum Here: http://investor-forum.thesubway.com/ NextPhase Wireless, Inc. (OTCBB: NPHS), a nationwide developer ofWiMAX-ready networks and provider of advanced...

Decision Makers

Name (plus bio) Position
Geert Cauwenbergh PhD Chief Executive Officer
Braham Shroot Chief Scientific Officer
Chuck Nomides Chief R&D Officer
Nicole Eyben Vice President, Commercial, Operations, Europe
Joan Chypyha General Manager, Canada
Anita Highton Director
Koen Rossem Director
Srinivas Akkaraju Director

Board of Directors

Name (plus bio) Position
Albert C. Bristow Board of Directors
Nicholas Simon Board of Directors
Organization Position Status
RHEI Pharmaceuticals, Inc. Chief Executive Officer Current
Barrier Therapeutics, Inc. Chief Executive Officer Current
The Triana Group, Inc. Founder Current
Health Care, Inc. Trade Advisor Current
Barrier Therapeutics, Inc. Board of Directors Current
Biotechnology Council of New Jersey, Inc Vice-Chairman Current
Upstream Biosciences Inc. Board of Directors Current
Dara Biosciences, Inc Board of Directors Current
The Triana Group, Inc. Board of Directors Current
Ablynx Board of Directors Current
Euroscreen Sa Board of Directors Current
Johnson & Johnson Vice President of Technology, Consumer and Personal Care Products Former
Barrier Therapeutics, Inc. Founder Former
Dermatology Ltd Former
Intercept Inc Board of Directors Former
The Faculty Ph.D. In Medical Sciences Former
Catholic University of Leuven Ph.D. In Medical Sciences Former
Organization Position Status
Barrier Therapeutics, Inc. Chief Scientific Officer Current
Organization Position Status
Barrier Therapeutics, Inc. Chief R&D Officer Current
Organization Position Status
Barrier Therapeutics, Inc. Vice President, Commercial, Operations, Europe Current
Barrier Therapeutics, Inc. General Manager Former
Barrier Therapeutics, Inc. General Manager Former
Organization Position Status
Barrier Therapeutics, Inc. General Manager, Canada Current
Barrier Therapeutics, Inc. General Manager Former
Organization Position Status
Barrier Therapeutics, Inc. Director Current
Barrier Therapeutics, Inc. Director Former
Organization Position Status
Barrier Therapeutics, Inc. Director Current
Barrier Therapeutics, Inc. Director Former
Organization Position Status
Barrier Therapeutics, Inc. Board of Directors Current
Barrier Therapeutics, Inc. General Counsel and Secretary Former

Mr. Simon has served as a member of our board of directors since June 2002. In February 2005, Mr. Simon co-founded Clarus Ventures, LLC, a venture capital firm focused on life sciences companies. Mr. Simon has been a general partner of MPM BioVentures III, a healthcare venture capital fund, since October 2001. From April 2000 to July 2001, Mr. Simon was chief executive officer and founder of Collabra Pharma, Inc., a pharmaceutical company. Mr. Simon served in various management positions at Genentech, Inc., including its vice president of business and corporate development. Mr. Simon is currently on the board of directors of Sientra, Inc., and several pharmaceutical companies: Barrier Therapeutics, Inc., Neosil, Inc., QuatRx Pharmaceuticals Company, Pearl Therapeutics, Inc., Poniard Pharmaceuticals, Inc., and Verus Pharmaceuticals, Inc. He is also on the advisory council of the Gladstone Institute, a private not-for-profit research institute affiliated with the University of California, San Francisco. Mr. Simon received a bachelor of sciences degree in microbiology from the University of Maryland and a masters in business administration in marketing from Loyola College.

Organization Position Status
Quatrx Pharmaceuticals Co Managing Director, Clarus Ventures and General Partner, Mpm Bioventures III Current
Clarus Ventures, LLC Managing Director Current
Clarus Ventures, LLC Founder Current
MPM Capital Limited Partnership Affilliate General Partner Current
ARYx Therapeutics Inc Board of Directors Current
Rigel Pharmaceuticals, Inc. Board of Directors Current
Quatrx Pharmaceuticals Co Board of Directors Current
Barrier Therapeutics, Inc. Board of Directors Current
Achillion Pharmaceuticals, Inc Board of Directors Current
CoTherix, Inc. Board of Directors Current
Verus Pharmaceuticals Board Director Current
Loyola College in Maryland M.B.A. Former
Loyola University M.B.A In Marketing Former
University of Maryland B.S. In Microbiology Former
Organization Position Status
Celgene Corporation Chief Financial Officer Current
The Panorama Capital, LLC Managing Director Former
Pharmos Corporation Co-Founder and Managing Director, Panorama Capital Current
Panorama, Inc. Co-Founder Current
Vela Pharmaceuticals, Inc. Current
New Leaf Current
Barrier Therapeutics, Inc. Director Current
Amarin Corporation Plc Board of Directors Current
Itero Biopharmaceuticals, Inc. Board of Directors Current
Pharmos Corporation Board of Directors Current
Seattle Genetics, Inc. Director Current
The Panorama Capital, LLC Co-Founder Former
Genentech, Inc. Senior Manager Former
Strategic Consulting Group Principal Former
Stanford University School of Medicine M.D. Former
Rice University Ph.D. in Immunology Former
Stanford University M.D. Former
Rice University B.A. Degrees Former
Rice University Degrees In Biochemistry and Computer Science Former
advertisement
     BTRX $1.00 0.00 (0.00% )
Intraday | 3 Month | 6 Month | 1 Year
Average Volume 114
Shares Outstanding 232.96K
Market Cap 233.0K
Year High 4.16
Year Low 0.3
Earnings Per Share N/A
P/E Ratio -
Dividend N/A
Yield N/A
Glass Door

Pharma Industry Companies

Company Employer Rating
Pfizer 3.0
IndustryTop Rated

Brought to you by CBS MoneyWatch.com

advertisement